Dr. Idris Badmus Joins XYTOS Inc. as Director

INDIANAPOLIS--(BUSINESS WIRE)--XYTOS, Inc. (OTC:XYTS), announced today that Dr. Idris Olagoke Badmus has been appointed as a Director of the company and it’s Chief Scientific Officer.

Dr. Badmus has a first degree in Virology from the University Of Ilorin and a Doctorate in Pharmacology, he is the founder and President of the African Center Foundation (ACF) which has over 200,000 members and is presently active in seventeen countries working in the African communities to develop local industries and primary health care. ACF is also an organization in Consultative Status with The United Nations.

In addition to serving as President of ACF, Dr. Badmus is also the CEO of the African Network Inc. and the Afrosea Seafood Group, which operates Seafood Plants in West African countries of Guinea, the Gambia and Nigeria. In the last fifteen years, Dr. Badmus has developed an extensive network of companies active in the areas of marketing, distribution and food production in more than fifty African communities. Dr Badmus is also an award winning poet and author. His collection of poetry, The Vision of Peace has won awards from the International Society of Poets and other institutions, and his published works include the Bloody Robots, Black Scorpion and My World Series. In 1994, Dr. Badmus started an international News Magazine called Africa Today, which is published in English, French and Italian.

Commenting on the appointment of Dr. Badmus, Tim Cook, Chairman and CEO of XYTOS said, “we are very excited to have Dr. Badmus agree to become a member of our Board; he is a world-class executive and a person whose values align exactly with XYTOS’ Mission and whose experience will be instrumental in the execution of the company’s development strategy. Equally important is the fact that Dr. Badmus opens the door to introduce the XYTOS Bio-Medical Technology not only to the African continent but also in the other seventeen countries where the African Center Foundation (ACF) has a presence, and eventually assisting the company in establishing global recognition and delivering great value to patients of life-threatening diseases, partners, employees and shareholders worldwide.”

About XYTOS

XYTOS is a Bio-Medical Technology Company, concentrating on the research, development and introduction of next generation Bio-Medical products and medical procedures, including Stem Cell Therapies, Tissue Engineering and Cellular Medicine and non-invasive and Cancer therapies. For more information on the Company, visit the Company’s website at www.xytos.com.

Forward-Looking and Cautionary Statements: Certain statements,, if any, contained herein, including, without limitation, statements containing the words “believes”, “intends” and other words of similar import, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of XYTOS, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. XYTOS, Inc. disclaims any obligation to update or to announce publicly the results of any revision of the forward-looking statements contained or incorporated by reference herein to reflect future events or developments.